Listed by the USPTO as HANEY, AMANDA MARIE
Tech Center 1600 • Art Units: 1634 1682 1693
This examiner grants 36% of resolved cases
HANEY, AMANDA MARIE has resolved 724 cases in Tech Center 1600 and Art Unit 1634. The allowance rate is 36.5%, and the median time to allowance is 1276 days. The substantial record supports treating the outcome as a meaningful prosecution signal, while the timing indicates a need for deliberate portfolio scheduling.
The interview lift is 45.0%, showing a meaningful measured association with allowance. Practitioners may consider interviews early enough to address claim interpretation and prior-art issues before prosecution becomes prolonged. The listed companies are The Medical College of Wisconsin Inc., Oxford Nanopore Technologies PLC, and 10x Genomics Inc. The principal firms are WOLF GREENFIELD & SACKS, P.C., CASIMIR JONES, S.C., and FOLEY & LARDNER LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17612610 | PROTOCOL FOR DETECTING INTERACTIONS WITHIN ONE OR MORE DNA MOLECULES WITHIN A CELL | Non-Final OA | Oxford Nanopore Technologies PLC |
| 18344339 | METHODS FOR DETERMINING A LOCATION OF A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE | Non-Final OA | 10x Genomics, Inc. |
| 18628011 | DIGITAL SEQUENCE ANALYSIS OF DNA METHYLATION | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17047006 | NON-INVASIVE DETECTION OF RESPONSE TO IMMUNOTHERAPY | Final Rejection | The Johns Hopkins University |
| 17416510 | Optimizing Detection of Transplant Injury by Donor-Derived Cell-Free DNA | Non-Final OA | The Regents of the University of California |
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin, Inc. |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin, Inc. |
| 18548972 | ISOTHERMAL AMPLIFICATION OF PATHOGENS | Non-Final OA | BECTON, DICKINSON AND COMPANY |
| 18548865 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18038915 | METHOD FOR DETECTING SEVERITY OF ATOPIC DERMATITIS | Final Rejection | KAO CORPORATION |
| 17353279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | Non-Final OA | Myriad Genetics, Inc. |
| 17905129 | METHODS OF USING A MULTI-ANALYTE APPROACH FOR DIAGNOSIS AND STAGING A DISEASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18271654 | COMPOSITIONS AND METHODS FOR INSTANT NUCLEIC ACID DETECTION | Non-Final OA | Wuhan University |
| 17344792 | METHOD FOR ISOLATING POLY(A) NUCLEIC ACIDS | Non-Final OA | QIAGEN GmbH |
| 18683116 | BIOMARKER FOR TRICHOTHECENE TOXICITY | Non-Final OA | DSM Austria GmbH |
| 18580444 | COMPOSITIONS AND METHODS FOR DETECTION OF COLORECTAL CANCER | Non-Final OA | Mercy Bioanalytics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy36.5% of resolved applications examined by Amanda Marie Haney were allowed (724 resolved cases), compared with 30.4% across Art Unit 1634 over the last five years.
This examiner's interview lift is +45.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Amanda Marie Haney took 1,276 days on average from filing to allowance.
Amanda Marie Haney examines applications in Art Unit 1634 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
